Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15381
UPID:
NVL_HUMAN
Alternative names:
-
Alternative UPACC:
O15381; B4DMC4; B4DP98; Q96EM7
Background:
The Nuclear valosin-containing protein-like plays a pivotal role in cellular homeostasis, engaging in the assembly of the telomerase holoenzyme and influencing telomerase activity through its interaction with TERT. It is crucial in pre-rRNA processing pathways and regulates 60S ribosomal subunit biogenesis in the nucleolus. Its ATPase activity is essential for releasing specific assembly factors from pre-60S ribosomal particles.
Therapeutic significance:
Understanding the role of Nuclear valosin-containing protein-like could open doors to potential therapeutic strategies.